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There is substantial epidemiological evidence pointing to an increased incidence of breast cancer and morbidity in obese,
prediabetic, and diabetic patients. In vitro studies strongly support metformin, a diabetic medication, in breast cancer therapy.
Although metformin has been heralded as an exciting new breast cancer treatment, the principal consideration is whether
metformin can be used as a generic treatment for all breast cancer types. Importantly, will metformin be useful as an inexpensive
therapy for patientswith comorbidity of diabetes and breast cancer? In general,meta-analyses of clinical trial data from retrospective
studies in whichmetformin treatment has been used for patients with diabetes and breast cancer have a positive trend; nevertheless,
the supporting clinical data outcomes remain inconclusive. The heterogeneity of breast cancer, confounded by comorbidity of
disease in the elderly population, makes it difficult to determine the actual benefits of metformin therapy. Despite the questionable
evidence available from observational clinical studies and meta-analyses, randomized phases I–III clinical trials are ongoing to test
the efficacy of metformin for breast cancer. This special issue review will focus on recent research, highlighting in vitro research
and retrospective observational clinical studies and current clinical trials on metformin action in breast cancer.
1. Introduction
Cancer and diabetes are two of the most common chronic
diseases worldwide [1] with a strong association between
the two diseases [2, 3]. Substantial evidence exists indicating
that the risk of developing and dying from breast cancer is
higher in diabetic patients compared to nondiabetic patients,
excluding all other diseases [2]. Metformin, a biguanide
oral antidiabetic drug, commonly used to treat type 2
diabetes mellitus has aroused much interest in comorbidity
(diabetes/cancer) treatment, and emerging evidence from in
vitro and epidemiological studies suggests that metformin
improves the overall survival for cancer/diabetic comorbidity
patients [2, 3]. In vitro experimentation supports metformin
as a strong candidate for treatment of breast cancer, where it
has been shown to increase breast cancer cell death. However,
the use of metformin as a comorbidity treatment, or breast
cancer preventative therapy, in retrospective clinical meta-
analyses studies is controversial.Metformin, on the one hand,
has been shown to decrease cancer incidence and increase
survival [3–6], while on the other hand no such association
has been observed in other studies [7].
This special issue review brings together recent in vitro
research supporting metformin as a wide-ranging treatment
for most breast cancer subtypes, including the hard to treat
triple negative subtype. Importantly, this paper will provide
an overview of the recent contradicting meta-analyses and
retrospective observational clinical studies focusing on met-
formin as a therapeutic agent for breast cancer.
1.1. Changing Metabolism Linking Diabetes and Cancer. For
over a century, disturbances in cellular metabolism intrinsi-
cally linking diabetes and cancer have been recognized [8, 9].
One of the hallmarks of cancer is the reprogramming of
energy metabolism to fuel cancer cell growth and division
[10]. First proposed by Otto Warburg in 1924, cancer cells
hijack cellular metabolism to favour aerobic glycolysis (high
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glucose demand) for energy needs in preference to mito-
chondrial oxidative phosphorylation [11]. Although aerobic
glycosylation is an inefficient energy process, the bioenergetic
demands of a cancer cell favour fast nutrients in the form
of excess glucose for fast bursts of energy to fuel all the
molecular components for DNA replication and cell divi-
sion. Simplistically, prediabetes is inefficient processing of
intracellular glucose, which leads to insulin resistant cells,
hyperinsulinemia (increased insulin), and hyperglycemia
(increased blood glucose levels). Elevated insulin levels have
been shown to have mitogenic effects and constitute an
increased risk factor for breast cancer [12]. An excessive
supply of glucose in the bloodstream, as evidenced in diabetic
patients, may provide the necessary nutrients to feed cancer
cells; hence, the proposal that diabetic treatments reduce
glucose in the bloodstream may prove beneficial for cancer
prevention and patient therapy [13]. Metformin is commonly
used in the treatment of type 2 diabetes mellitus to combat
insulin resistance by reducing the amount of available glucose
in the blood, as aptly described by Jalving and colleagues [13]
“taking away the candy.” The antidiabetic drug metformin is
emerging as a potential, efficient, preventative, and adjuvant
therapy for many cancer types [14–17].
1.2. Safety of Metformin in Diabetic Treatment. For over than
50 years, metformin has been one of the most effective,
well tolerated, antidiabetic treatments prescribed worldwide
[18]. Metformin taken alone is a relatively safe drug for
clinical use with only mild side effects documented including
gastrointestinal disturbances (diarrhea, nausea, and irritation
of the abdomen) [19]. The major toxicity reported is lactic
acidosis, though this is very rare (9 per 100,000) [20]. A recent
report suggests metformin is associated with impairment
of cognitive function and these studies are ongoing [21].
The overall safety of metformin with minimal and rare side
effects adds to its attractiveness as a potential breast cancer or
comorbidity treatment for cancer patients with diabetes.
1.3. Diabetes and Breast Cancer. Evidence from epidemio-
logical studies strongly supports that prediabetes, preexisting
diabetes mellitus, and obesity are risk factors for cancer with
a poorer outcome reported for breast cancers occurring in
diabetic patients compared to nondiabetic patients [2, 22–
26]. A meta-analysis of twenty clinical trials involving more
than 1.9 million cancer patients with or without diabetes
supported a significant increase in combined incidence and
death from breast cancer [2]. This mega-study agreed with
previous findings by Peairs and colleagues who reported
comorbidity of breast cancer and diabetes was associated
with a 49% increased risk of death from any cause and
increased adverse effects in response to chemotherapy [24].
Prediabetes and hyperinsulinemia in breast cancer patients
have also been associated with higher mortality rates [27–
29]. Interestingly, a meta-analysis by Boyle and colleagues
showed that the association between diabetes and breast
cancer was restricted to diabetesmellitus type 2 (not type 1) in
postmenopausal women and no such association was evident
between diabetes and prediabetic conditions and breast
cancer in premenopausal women [30]. The link between the
onset of prediabetes, type 2 diabetes mellitus, and a higher
risk of breast cancer diagnosis comes with new insights into
how diabetic treatments influence breast cancer outcomes
[2, 17, 24, 30]. Metformin, a well-tolerated insulin-sensitizer,
has shown promise in reducing cancer risk or has no negative
effect [29, 31–33]. Recently, mining of over 100,000 electronic
medical records from Vanderbilt University Medical Center
and Mayo Clinic by Xu and colleagues showed that the use
of metformin significantly reduced cancer risk, including
breast cancer, compared to patients who are not using
metformin and are independent of diabetes status [6], thus
providing additional support for metformin use in future
cancer treatment regimens. Consequently, there has been
much interest in understanding themechanism ofmetformin
action and exploring its efficacy in breast cancer therapy.
Equally, there are a number of studies that do not support the
observation of a reduction in breast cancer risk in diabetic
and nondiabetic patients being treated with metformin and
these findings are discussed.
In contrast, diabetic treatments, such as sulfonylureas,
have been shown to increasemortality in patients with cancer
and type 2 diabetes and insulin replacement has been shown
to increase mortality due to its mitogenic effects [34–40].
However, it is noted that, in one meta-analysis retrospective
study, data extracted from the Hong Kong Diabetes Registry
reported that insulin replacement therapy reduced cancer
risk [41]. An increase in body mass index (BMI) or obesity
is associated with cancer risk and this study did not account
for BMI [42]. Given the lowBMI in theAsian population, this
may contribute to the differences in the results [43].
2. Mechanism of Metformin Action to
Inhibit Cancer
The exact molecular mechanism of metformin action is not
clearly understood and has been hotly debated [44, 45]. Nev-
ertheless, metformin action undisputedly has been shown
to increase insulin sensitivity in vivo, resulting in reduced
plasma glucose concentrations, increased glucose uptake, and
decreased gluconeogenesis [46, 47]. High insulin levels are
associated with increased breast cancer risk and poor patient
survival outcome [17, 48]; therefore, metformin directly and
indirectly reduces cancer cell proliferation through reduction
of insulin levels and blood glucose levels. In the context of
breast cancer risk, metformin has been shown to decrease
circulating hormones such as androgen and estrogen where
elevated levels are linked with postmenopausal breast cancer
development [49, 50]. Thus metformin treatment may serve
as a contributory factor in decreasing breast cancer risk.
The concept that cancer cells undergo metabolic repro-
gramming in favour of glycolysis is generally accepted.
Metformin acts by interfering with cellular processes that
facilitate insulin signalling and glucose synthesis. Some of
these proposed signalling pathways are described in this
section and illustrated in Figure 1.
There is general consensus that the organic cation trans-
porter (OCT1) plays a major role in mediating the first





























Figure 1: Mechanisms of metformin action to inhibit cancer. Metformin disrupts circulating glucose and insulin levels and reduces
inflammation. The organic cation transporter (OCT1) mediates the first step in metformin cellular response [51–53]. (1) Metformin activates
the AMPK-P pathway through inhibition of Complex 1 of the mitochondrial respiratory chain [54, 55]. This leads to the inhibition of mTOR
and thus loss of cell proliferation and inhibition of glucose synthesis [56–59]. (2) LKB1 may act as an intermediatory of AMPK activation
[60, 61]. (3) Metformin blocks cAMP and PKA, which in turn antagonizes glucagon action [62]. (4) Metformin acts as an antifolate hindering
DNA replication [63]. (5)Metformin induces an anti-inflammatory response via the Src-mediatedNF-𝜅Β pathway [64]. (6)Metformin action
is implicated in both AMPK dependent and independent inhibition of the angiogenesis process [65].
step in metformin cellular response [51–53]. Shu and col-
leagues demonstrated that genetic variation in theOCT1 gene
reduced hepatic uptake of metformin and altered the efficacy
of metformin suggesting that patients with reduced response
to metformin may be screened for OCT1 mutations [51]. The
most widely accepted mechanism of metformin action is, by
indirect activation of the central energy sensor, adenosine
monophosphate-activated protein kinase (AMPK), which
also plays a key role in insulin signalling [54, 55]. Activa-
tion of AMPK has been shown to inhibit the mammalian
target of rapamycin (mTOR) and therefore inhibit patholog-
ical cell proliferation in different cancer cell lines [56–59]
(Figure 1(1)). Phosphorylation of AMPK by serine-threonine
kinase 11/liver kinase B1 (STK11/LKB1) has also been reported
to be an upstream event in metformin action [60, 61] despite
more recent evidence questions whether LKB1 is required for
metformin action [58, 66] (Figure 1(2)). Whereas the focus
of metformin action has been directed towards reduction of
glucose synthesis through the AMPK pathway (Figure 1(1)),
Miller and colleagues showed that metformin antagonism of
glucagon action was responsible for reducing fasting glucose
levels [62] (Figure 1(3)).
2.1. Metformin, Cancer, and the Mitochondria Conundrum.
Upstream of AMPK-activation both mitochondria-
dependent and -independent mechanisms have been
described as precursors of AMPK activation. Metformin
has been described as a “mitochondrial poison” through
inhibition of Complex 1 of the mitochondrial respiratory
chain leading to AMPK activation and reduction of glucose
synthesis [54, 55] (Figure 1(1)). Based on the premise that
metformin is a weak “poison,” Salem and colleagues proposed
that metformin could be useful as an anticancer therapy
targeting mitochondrial metabolism [67]. Metformin also
affects the mitochondrial redox state through inhibition
of mitochondrial glycerophosphate dehydrogenase, which
leads to suppression of gluconeogenesis [68]. These studies
were confirmed in mouse and rat models using metformin
treatment doses that achieved similar plasma concentrations
to those observed in type 2 diabetes patients treated with
metformin [68].
Alternatively, mitochondrial-independent AMPK activa-
tion has been described whereby metformin acts in a similar
manner to an antifolate, a member of the antimetabolite class
of chemotherapy drugs, and inhibitsDNA replication and cell
proliferation [63] (Figure 1(4)).
Hirsch and colleagues implicated metformin in blocking
the inflammatory response through inhibition of a step(s) in
the Src-mediated-nuclear factor kappa B (NF-𝜅Β) signaling
pathway [64] (Figure 1(5)). These findings are especially rele-
vant as a preventative measure in obesity-associated inflam-
mation and cancer progression. Others have shown that
metformin may be associated with inhibition of the angio-
genesis process, as shown in endothelial cells, via AMPK-
dependent and -independent pathways [65] (Figure 1(6)). As
new vascular formation is essential for tumour growth, this
effect would assist in the prevention of cancer development.
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In summary, metformin has been reported to have
both direct and indirect effects on a number of metabolic
pathways. Whilst the majority of laboratory research has
focused on the mitochondrial-AMPK signalling pathway,
new research has elucidated new mechanisms of metformin
action, some of which are highlighted in Figure 1. Nonethe-
less, the mode of metformin action is still unclear and
under investigation.The consensus is that themost important
therapeutic endpoints of metformin are reduction in blood
glucose level, and action as an insulin sensitizer, which is
beneficial to patients with diabetes and/or potentially reduces
the risk of most cancers including breast cancer.
3. Metformin and Breast Cancer
In Vitro Studies
Since the benefits of metformin treatment for breast cancer
patients were reported in 2005 [32], an increasing number
of articles assessing its anticancer properties have been pub-
lished. Highlighted here are some of the important findings
from the in vitro studies linking metformin treatment and
breast cancer outcome.
3.1. Breast Cancer Classification. Breast cancer is heteroge-
neous and, as such, different breast cancer subtypes are
known to have distinct molecular profiles [69–74] and
variable responses to different treatments. Based on the
differential expression of various genes, breast cancer has
been categorised into five major distinct molecular sub-
types with prognostic significance: luminal A; luminal B;
overexpression of HER2; also known as ErbB2; breast-like;
and basal-like/triple negative [69]. Triple negative breast
cancers have been further classified into six distinct subtypes:
immunomodulatory, mesenchymal, mesenchymal stem-like,
luminal androgen receptor, basal-like 1, and basal-like 2 [75].
In addition, there are at least seventeen rare subtypes defined
[76]. Response to therapy is dependent on the pathology and
classification of the breast tumour. The most predominant
subtype, luminal A, is known to have the best prognosis with
HER2 and the basal-like triple negative subtype has the worst
outcome [77]. Nevertheless, many breast cancers recur and
acquire resistance to conventional treatments. Metformin is
being investigated in vitro in different breast cancer cell types,
reviewed below, and an understanding of the mode of action
in diverse breast cancer cell types is providing some insights
into drug resistance. One of the leading questions is can
metformin be used as a generic therapy for all breast cancer
subtypes?
3.2. Metformin as Mono- or CombinationalTherapy for Breast
Cancer. There are enormous differences in clinical response
to metformin monotherapy in diabetic and cancer patients;
hence, the drug is generally used in combination with other
treatments. The current challenge is to understand why this
drug has reduced efficacy in some patients and to modify
drug therapy for better outcome for individual patients.There
have been a number of recent reports showing synergistic or
enhanced effects on endpoints such as increased apoptosis
and cell death in breast cancer cell lines when metformin
is used in combination with chemotherapeutic drugs and
with targeted therapies, providing a strong rationale for the
use of metformin in clinical treatment regimens [78–80].
Metformin monotherapy has been shown to promote cell
cycle arrest in both ER+ and ER− breast cancer cell lines
[78, 80]. Metformin was reported to markedly suppress, but
not completely abrogate, proliferation of breast cancer and
cancer stem cells whilst being less toxic to normal stem cells
[81]. These findings are important as a small proportion of
breast cancer stem cells are believed to be the source of cancer
recurrence [64]. Interestingly, cell cycle inhibition in a study
by Lee and colleagues was significantly enhanced when the
temperaturewas increased to 42∘Csuggesting thatmetformin
may be more toxic to breast cancer patients with elevated
body temperature [81]. In these experiments, metformin
cytotoxicity appeared to be mediated through AMPK/mTOR
activation [81].
3.3. Metformin Effects on Basal-Like/Triple Negative Breast
Cancers. Triple negative breast cancers occur in a minority
of breast cancer patients and such patients have a very poor
prognosis [82]. These types of tumours are very aggressive
and are associated with high morbidity and mortality due to
their fast proliferation and propensity for metastasis. Their
failure to express ER/PR and HER2 makes them resistant to
antihormonal therapies and herceptin. Many triple negative
breast tumours demonstrate epithelial mesenchymal transi-
tion (EMT) and stem cell-like properties and may lie dor-
mant making them extremely difficult to treat with current
chemotherapy treatments. Metformin has been shown to be
a promising adjuvant treatment for triple negative breast
cancers [58, 67, 78, 82–87] where Stat3 has been shown to
be a critical regulator of metformin action [87], and it has
also been shown to directly inhibit the enzymatic function
of hexokinase I and hexokinase II [86]. However, not all
studies have shown thatmetformin induces apoptosis and cell
cycle arrest in the triple negative cell model, MDA-MB-231,
and it has been suggested that this is a function of glucose
homeostasis [58, 85].
3.4. Metformin Efficacy Is Dependent on Glucose Homeostasis.
Circulating glucose levels may prove to be an important
factor in response to metformin treatment in cancer patients.
Menendez and colleagues reported that metformin lethality
was enhanced in breast cancer cells that had undergone
glucose deprivation [88]. Their studies showed metformin
was protective in normal cells in the presence of physiological
amounts of glucose, whereas it caused cell cycle arrest
in breast cancer cells. Conversely, withdrawal of glucose
induced breast cancer cell death independent of the following
subtypes: ER+, HER2+, and triple negative [88]. Further
studies have also confirmed that the failure to maintain glu-
cose homeostasis results in a more aggressive triple negative
breast cancer phenotype [85]. Moreover, in hyperglycemic
conditions, Zordoky and colleagues showed that a surplus
of glucose supply rescued the triple negative MDA-MD-
231 cells from metformin induced cell death and suggested
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that the bypass was due to the generation of enough energy
for proliferation through aerobic glycolysis using the excess
glucose [58]. Based on the laboratory evidence, it has been
advocated that glucose monitoring of breast cancer patients
may provide some insight into patient response tometformin
and that pharmacological deprivation of glucose combined
with metformin treatment may benefit patients with high
glucose levels [88].
3.5. Use of Metformin to OvercomeMultidrug and Chemother-
apy Resistance in Breast Cancer Cells. The emergence of
multidrug/chemotherapy resistant cells within a tumour
population is a major obstacle for many cancer patients.
There is now compelling evidence to suggest that metformin
resensitizes cells and cooperates with some anticancer drugs
to improve efficacy through reprogramming of the metabolic
cellular pathways [89, 90]. A recent study showed the rever-
sal of multidrug resistance in breast cancer cells through
activation of AMPK/mTOR by metformin [90]. In addition,
metformin promoted 5-FU-induced apoptosis, consistent
with its proposed role as a pseudo metabolite, and reversed
epithelial mesenchymal transition (EMT), a critical pheno-
typic switch associated with enhanced capacity of cells for
invasion, metastasis, and chemoresistance [90]. Metformin
sensitisation to chemotherapy has also been demonstrated
in breast cancer cells overexpressing aldehyde dehydrogenase
(ALDH), an enzyme linked to chemoresistance in breast
cancer cells that also feature an EMT phenotype [91]. Poten-
tially, small doses of metformin could be used as an adjuvant
therapy to prevent some chemotherapy resistant phenotypes
and prevent EMT transition.
ErbB2-positive (HER2/neu) breast cancer cells are usu-
ally treated with lapatinib (a dual inhibitor of the EGRF
and ERBB2/HER2 tyrosine kinase inhibitor) as a first
line monotherapy [92–94]. Short-lived clinical responses
in ErbB+ breast cancers are due to acquired resistance
to lapatinib. Komurov and colleagues showed that forcing
ErbB2 drug-sensitive cells into glucose-deprivation made
themmore resistant to lapatinib [95]. In linewith the glucose-
deprivation concept described above, metformin counter-
acted lapatinib-induced toxicity [95]. Combinational therapy
of metformin and conventional chemotherapy treatment,
such as carboplatin, doxorubicin, and paclitaxel, were shown
to contribute to synergistic inhibition of cell proliferation
in most breast cancer cell types [78]. The use of metformin
to counteract or prevent tamoxifen resistance has also been
explored in breast cancer cell lines with positive results. The
combination of tamoxifen and metformin has been shown to
augment the apoptotic effect of tamoxifen alone [79, 96]. As
demonstrated, metformin-induced alteration in cancer cell
metabolism appears to be an effective adjuvant therapy for
many different types of chemoresistant breast tumours.
3.6. Metformin Failure in Prevention and Treatment of Breast
Cancer. Resistance to treatment is inherent in breast cancer
and metformin is proving to be no exception. TheMenendez
group used chronic metformin exposure to establish met-
formin resistant cells [97]. Acquired metformin resistance
triggered a transcriptome reprogramming event in breast
cancer cells and the cells developed a highly metastatic
stem-like expression profile making these cancer cells more
difficult to treat [97]. Metformin efficacy was also reduced
in breast cancers overexpressing BCA2, a gene associated
with an AMPK-suppressive function [98]. The BCA2 gene
is overexpressed in >50% of breast cancer patients mak-
ing it a potential target/adjuvant therapy for metformin
resistant breast cancer cells [98]. These studies advocate an
individualized genetic approach targeting specific genetic
mutations, such as BCA2, with combinational treatment to
reduce acquired resistance to metformin.
In summary, the heterogeneous nature of breast cancer
makes the disease difficult to treat. However, in vitro studies
strongly support a role for metformin, which is one of the
most commonly used diabetic medications, as a generic ther-
apy for most, if not all, breast cancer subtypes. Furthermore,
the potential to use metformin as a dual treatment for cancer
and diabetes is an important consideration with the increas-
ing incidence of comorbidity worldwide. As highlighted in
these in vitro studies, the mechanism of metformin action
is still unclear and affects more than one cellular signaling
pathway. Breast cancer is inherent and acquired resistance to
metformin is still to be explored.
4. Breast Cancer Retrospective Observational
Clinical Studies
In vitro studies examining the use of metformin as a breast
cancer therapy for most breast cancer subtypes have been
very promising; however, translating these positive findings
into reduced breast cancer incidence and improved clinical
outcomes with metformin use has come with very mixed
and contradictory reviews. Table 1 summarises the important
points arising from the recentmeta-analyses as highlighted in
this section.
The subtype of breast cancer, the presence or absence
of hormones and hormone receptors; the age of the patient
(pre- or postmenopausal); comorbidities, such as prediabetes,
diabetes, and other diseases; and comorbidity treatments
all impact on the efficacy of relapse-free survival (RDFS),
metastasis-free survival (MDFS), and patient overall disease-
free survival (OS). The majority of breast cancers are present
in postmenopausal women where there is a higher risk of
comorbidity with diabetes, obesity, and other age-related
diseases. A number of meta-analyses of clinical study data
support the use of metformin as a breast cancer adjuvant
treatmentwith improved patient outcome in postmenopausal
women [22, 23, 99, 114]. A study by Currie and colleagues
showed that mortality increased in elderly breast cancer
patients with diabetes, and metformin treatment improved
survival rates in comparison with other diabetic treatments
(sulfonylureas and insulin) and compared to a nondiabetic
patient cohort [29]. In agreement with these findings, a
study by Kiderlen and colleagues showed that metformin
increased the RDFS in elderly breast cancer patients with
diabetes compared to nondiabetic patients, with no difference
between patients with other comorbidity diseases [100]. In
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a retrospective clinical meta-analysis of 28 separate studies
by Zhang and Li, they found that, in breast cancer patients
with existing diabetes, metformin reduced the mortality of
breast cancer and reduced the risk of breast cancer by 6%
[3]. In addition, elderly nondiabetic breast cancer patients
had similar survival rates to diabetic breast cancer patients
using metformin with elderly diabetic patients treated with
metformin having a higher RFS period [100]. Metformin
was also associated with reduced incidence of invasive breast
cancer in postmenopausal women [99].
Can Metformin Be Used as a Generic Therapy for All Breast
Cancer Sub-Types? Xiao and colleagues looked at specific
breast cancer subtypes and found that the nondiabetic
metformin group of patients with Luminal A (ER+/PR+),
Luminal B (high ki67), and luminal B (HER-2/NUE+) had
better prognosis compared to the nondiabetic group not
treated with metformin. However, in diabetic groups, only
luminal A and luminal B (HER-2/NUE+) metformin treated
patients had better prognosis than nonmetformin group
[101]. Concurring with these findings, in independent studies
metformin showed decreased cell proliferation in insulin
resistant, luminal B subtype breast cancer patients although
overall metformin did not significantly alter cell proliferation
in this patient cohort [102] and diabetic patients with HER2+
subtype had a better prognosis with metformin [115]. In
contrast, looking at patients’ data from 2005 to 2011, Besic and
colleagues indicated that the long-term use of metformin in
diabetic breast cancer patients does not associate with breast
cancer subtype distribution [103]. Berstein and colleagues
showed that postmenopausal diabetic breast cancer patients
treated with metformin as a monotherapy or metformin and
sulfonylureawere found to have higher progesterone receptor
(PR) tumours than patients treated with other antidiabetic
therapies leading to better response of these breast cancer
patients to hormone therapy [104]. In contrast, Besic’s group
found that there was no change in the rate of PR between
metformin and nonmetformin groups [103]. In this study,
253 patients (both pre- and postmenopausal patients) were
reviewed.
Although the studies described showed metformin to
have tantalizing promise as a comorbidity treatment for
cancer patients with diabetes and treatment for breast cancer
subtypes, most of these studies were inconclusive.
Not all meta-analyses reports showed a positive cor-
relation with improved patient mortality and metformin
treatment. Five recent reports, one comprised of a meta-
analysis of twenty-one observational studies subgrouped
by cancer type, did not show any significant reduction
in mortality in breast cancer patients [105–107, 116, 117].
Although there have been very promising in vitro studies
for the use of metformin in triple negative breast cancer
therapy, these reports have not been confirmed in clinical
observational studies where no significant impact on survival
outcome has been observed, even though there was a trend
towards reduced distant metastasis in these cohorts [108].
There are a number of examples where in vitro data did
not correlate with clinical observations. Samarajeewa and
colleagues found metformin specifically inhibited aromatase
expression in vitro [118], whereas Bershtein’s group found that
this did not translate to clinical samples where they observed
that metformin did not inhibit aromatase expression in
tumour samples from diabetic breast cancer patients [119]. As
metformin is a well-tolerated drug for diabetes with very few
side effects, the important question is that can we continue
to use this drug in combination with traditional cancer
therapies for comorbidity patients? One study by Ferro and
colleagues showed that metformin caused radiotoxicity in
breast cancer patients with diabetes compared to nondiabetic
patients and diabetic patients receiving alternative medica-
tions [109]. With the increasing comorbidity of breast cancer
with diabetes and other diseases in postmenopausal women,
combination comorbidity medication studies are imperative
to determine metformin interactive efficacy.
4.1. Metformin as a Breast Cancer Treatment Independent
of Diabetes. Despite the benefits of metformin to reduce
breast cancer risk in diabetic patients metformin is still
debatable; metformin is coming into prominence in its own
right as a breast cancer adjuvant treatment independent of
diabetes. As mentioned earlier, in addition to metformin’s
properties to reduce glucose and insulin in the bloodstream,
it has also been shown to reduce circulating androgen and
estrogen levels, which have well established mitogenic effects
in breast cancer [49, 50]. Endocrine resistant breast cancer in
obese postmenopausal women is partly mediated by insulin
resistance and changes in estrogen metabolism metformin
may also play a crucial role in preventing endocrine resis-
tant tumours. However, early Phase I clinical trials with a
combination of metformin with exemestane, an aromatase
inhibitor, in a cohort of obese nondiabetic postmenopausal
women, though well tolerated, showed no improved outcome
[120]. A prospective phase II clinical trial to test neoadjuvant
metformin with the aromatase inhibitor letrozole in ER+
postmenopausal nondiabetic women has been initiated to
evaluate the direct antitumour effects of metformin [110]
and it will be some time before the long-term benefits of
metformin use is realised.
4.2. Metformin Presurgical Trials in Breast Cancer Patients
without Diabetes. Four presurgical metformin clinical trials
to determine if metformin was able to modulate breast
tumour proliferation were conducted with mixed results.
Three clinical trials showed no significant difference in apop-
tosis when metformin was given before the surgery [102, 111];
conversely, one trial indicated a potential benefit according to
insulin-resistant status [112] and one trial provided support
for antiproliferative effects with metformin [113]. The major
limitation to of all these studies was the small sample size.
Despite the controversial retrospective meta-analyses
studies reported, currently there are at least 20 recruiting and
completed clinical trials, registered by the National Institute
of Health (NIH) USA, addressing the use of metformin with
combinational cancer therapies (https://clinicaltrials.gov/ct2/
results?term=breast+cancer+and+metformin&Search=Search)
. To date, the results of one study have been posted on the
NIH clinical trials site; however, due to the low numbers
BioMed Research International 9
in the patient cohorts, no meaningful results have been
recorded.
5. Conclusion
Overwhelming evidence supporting that type 2 diabetes
increases breast cancer risk makes the idea of using the
diabetic drug metformin as a preventative drug for cancer a
very exciting prospect. Still there are a number of unresolved
issues in metformin use for breast cancer treatment outlined
as follows.
Summary. Metformin Use for Breast Cancer Treatment. There
is strong epidemiological evidence to support an increase in
breast cancer incidence and death in prediabetic and diabetic
patients.
There is mounting evidence to suggest that diabetic
patients treated with metformin have reduced breast cancer
risk supporting metformin use as a preventative medication
for breast cancer.
In vitro studies strongly support the role for metformin
in treatment for most of, if not all of, the subtypes of breast
cancer, especially the hard to treat triple negative breast
cancers.
To date, meta-analyses of retrospective clinical trial data
on the use of metformin as a mono- or combined therapy
for comorbidity (patients with diabetes and cancer) are
equivocal supporting positive or no difference in survival
outcomes. Most studies are inconclusive and recommend
further confirmation.
Phase I clinical trials with a combination of metformin
with exemestane in a cohort of obese, nondiabetic post-
menopausal women, although well tolerated, showed no
improved outcome.
The majority of breast cancers patients are postmeno-
pausal women where there is increasing incidence of comor-
bidity, diabetes, and cancer. The heterogeneity of breast
cancer, confounded by comorbidity of disease in the elderly
population, makes it difficult to determine the actual benefits
of metformin as a mono- or adjuvant therapy for breast
cancer.
Prospective controlled clinical trial outcomes will be
important to provide more definitive answers regarding the
efficacy of metformin use in prevention and treatment for a
breast cancer. Ongoing clinical trials are open for metformin
as an adjuvant therapy for breast cancer.
The biology and mechanism of metformin action under-
pinning its use as an antidiabetic and antibreast can-
cer comorbidity treatment are likewise very compelling.
Although the mechanism of metformin action is not fully
understood, the in vitro evidence shows that metformin
is an effective inhibitor of cell proliferation and an acti-
vator of apoptosis in breast cancer cells and supports the
use of metformin as a mono- and/or adjuvant therapy
for breast cancer with some limitations as discussed. Data
from the retrospective meta-analyses investigating the use
of metformin in breast cancer have suffered from a number
of limitations and flawed assumptions. The meta-analyses
are retrospective observational studies only and were not
designed to specifically analyse the effects of metformin
as a preventative or adjuvant treatment in defined breast
cancer patient cohorts. Patient numbers and confounding
comorbidities limitedmany of the studies.Themajority of the
studies report a significant increase in breast cancer incidence
in postmenopausal type 2 diabetic, prediabetic, and obese
patients with higher prevalence of other comorbidities such
as cardiovascular disease. Retrospective studies to investigate
if the use of metformin as a preferred diabetic medication
actually reduced the incidence of breast cancer in these
population studies have been contentious and divided into
somemeta-analyses showing a decreased risk of breast cancer
incidence and others showing no effect. Other aspects that
can alter patient outcome after metformin treatment include
other medications taken, the different administration times
of taking the drugs, and the drug dosage. These need to be
taken into account in future studies. To date, metformin is
not approved for clinical use in breast cancer treatment by the
Food andDrugsAdministration (FDA) and is still considered
investigational. Even so, metformin is well established as an
inexpensive, relatively safe, and effective drug for diabetes,
prediabetes, and obesity and to extend this into breast cancer
treatment regimens may have both economic and clinical
benefits. Two important issues that are still to be resolved
are the safety of metformin in comorbidity treatments for
breast cancer and diabetes and the suitability of metformin
as a breast cancer therapy independent of diabetes. The
persuasive in vitro evidence and the optimistic retrospective
observational clinical meta-analyses studies on metformin
treatment for breast cancer have led to ongoing phases I–III
clinical trials. These studies are important for clarification of
the use of metformin in breast cancer prevention and breast
cancer treatment, particularly as it is a commonly used FDA
approved drug for diabetes. Prospective controlled clinical
trial outcomes will be important to provide more definitive
answers regarding the efficacy ofmetforminuse in prevention
and treatment for a breast cancer patients as well as its efficacy
in comorbidity treatments for diabetes, breast cancer, and
other diseases.
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